Two businesses have recalled eye drop brands due to safety concerns that could lead to infections and other complications.
The Food and Drug Administration (FDA) issued separate recall letters for certain eyedrops marketed by Pharmedica and Apotex after the businesses voluntarily withdrew multiple product lots from the market. The recalls were undertaken in conjunction with the FDA, according to both companies.
Recalled Eyedrop May Cause Infections
Apotex Corporation stated that it recalled its Brimonidine Tartrate Ophthalmic Solution with a concentration of 0.15 percent because container tops developed cracks. According to the corporation, the fissures may affect the sterility of the product, which could cause injury to consumers.
The recalled drops are intended for persons with glaucoma or ocular hypertension, according to the manufacturer, and were distributed in the United States between April 2022 and February 22, 2023.
Perfectly Soothing 15% MSM Drops were recalled by Pharmedica owing to contamination, which the company said could induce eye infections leading to blindness. The drops are available for purchase on Amazon and other online merchants. The company stated that it has not received any reports of product-related problems.
The Centers for Disease Control and Prevention recommended people last month to cease using a brand of over-the-counter eyedrops that, according to the CDC, has been linked to illnesses and at least one death.
The CDC reports that at least 55 people in 12 states have been diagnosed with multidrug-resistant bacterial infections that may be linked to EzriCare Artificial Tears. The infections have also resulted in irreversible visual loss and hospitalization, according to the CDC’s health advisory.
Read more: Warning: Anyone who brews a cup of tea at work is at risk of spreading ‘dangerous’ microbes
No Reported Injuries So Far
Two businesses recall eyedrop products due to safety concerns that could lead to infections and other complications.The eyedrops are distributed as Brimonidine Tartrate Ophthalmic Solution 0.15 percent and were sold from April through February of last year.
The eyedrops were made in Canada, according to an email from Apotex. No complaints of injuries resulting from the drops have been received by the company.
The most recent two recalls are unrelated to the recall that occurred last month.
The firms advised customers to return the items, consult a physician if they experienced adverse effects, and notify the FDA of any difficulties.
